Silke Allekotte

Silke Allekotte

Auto-generated profile, based on publicly available information

Silke Allekotte

ClinCompetence Cologne GmbH Cologne Germany

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 October 2023 in Allergy
Verified
Journal Article
Open access
Ralph MösgesRalph Mösges
Ralph Mösges
CZChristoph Zeyen
Christoph Zeyen
EREsther Raskopf
Esther Raskopf
CACengizhan Acikel
Cengizhan Acikel
HSHacer Sahin
Hacer Sahin
MCMiguel Casanovas
Miguel Casanovas
Background: There is still great need to develop new strategies to improve the efficacy of allergen immunotherapies with optimal safety standards for patients. A new promising approach is to couple allergoids to mannan. The objective of this phase IIa/IIb study was to identify the optimal dose of mannan-conjugated birch pollen allergoids for the short-course treatment of birch pollen-induced allergic rhinoconjunctivitis.Methods: For this prospective, randomized, double-blind, placebo-controlled, dose-finding study, 246 birch pollen-allergic adults received 0.5 mL placebo or 1000, 3000 or 10,000 mTU/mL of mannan-conjugated birch pollen allergoids at five pre-seasonal visits. Efficacy was assessed by comparing allergic rhinoconjunctivitis symptoms and use of anti-allergic medication during the peak of the birch pollen season 2020. Immunologic, tolerability and safety effects were also analysed.Results: The highest dose of mannan-conjugated birch pollen allergoids reduced the combined symptom and medication score during the peak birch pollen season by a median of 24.7% compared to placebo. The production of Bet v 1 specific IgG4 significantly increased in a dose-dependent manner (3.6- and 4.5-fold) in the 3000 and 10,000 mTU/mL groups. The Bet v 1 specific IgE/IgG4 ratio was also strongly reduced (up to -70%). No fatalities nor serious adverse events were reported, and no adrenaline was used. In total, four systemic reactions occurred (two grade I and two grade II).Conclusion: All doses of mannan-conjugated birch pollen allergoids can be considered as safe. Since the application of 10,000 mTU/mL resulted in the highest efficacy, this dose qualifies for further investigation.

9 November 2024 in Allergy
Verified
Journal Article
Open access
Ralph MösgesRalph Mösges
Ralph Mösges
EREsther Raskopf
Esther Raskopf
LKLudger Klimek
Ludger Klimek
OPOliver Pfaar
Oliver Pfaar
SZStefan Zielen
Stefan Zielen
MCMandy Cuevas
Mandy Cuevas
Background: Subcutaneous immunotherapy has emerged as an effective option for treating allergic diseases. Here, we assessed the clinical impact of the mannan‐conjugated birch pollen polymerized allergoid T502 in birch pollen‐induced allergic rhinoconjunctivitis. Methods: In this prospective, randomized, double‐blind placebo‐controlled phase III trial, 298 birch pollen–allergic adult patients were treated across 28 trial sites in Germany. Patients received either placebo or 23,000 mTU T502 subcutaneously over five pre‐seasonal visits. Efficacy was assessed by comparing the combined symptom and medication score (CSMS) between placebo and T502 during the peak birch pollen season 2022. Safety, tolerability and immunologic effects were also analyzed. Results: During the peak birch pollen season, the median CSMS of the T502 group was reduced by 33% ( p = 0.002) compared to placebo. The median daily symptom score and daily medication score were reduced by 30.4% ( p < 0.001) and 56.3% ( p = 0.045), respectively. Health related quality of life improved as reflected by reduction of RQLQ values by 31.5% ( p < 0.0001). Production of Bet v 1 sIgG4 and Bet v 1 sIgG increased up to 6.2‐fold and 3‐fold respectively in the T502 group ( p < 0.0001). The sIgE/sIgG4 ratio was strongly reduced in the T502 group at V7 (−62.9%, p < 0.0001). No fatalities nor serious adverse events were reported. In total, 16 systemic allergic reactions occurred (Grade I/II). Conclusions: Treatment with T502 significantly reduced symptoms and medication need in rhinoconjunctivitis patients. The treatment is well tolerated and safe.

30 April 2026 in Clinical & Experimental Allergy
Verified
Journal Article
Open access
PDF file
Ralph MösgesRalph Mösges
Ralph Mösges
FHFriederike Hüffmeier
Friederike Hüffmeier
LKLudger Klimek
Ludger Klimek
OPOliver Pfaar
Oliver Pfaar
CNChristian Neuhof
Christian Neuhof
EREsther Raskopf
Esther Raskopf
Background: Mannan‐conjugated allergoids represent an effective option for treating allergic diseases. This study evaluated the clinical impact of the mannan‐conjugated, polymerised birch pollen allergoid EP‐088_T502 in patients with birch pollen‐induced allergic rhinoconjunctivitis over 3 years. Methods: Following up to a double‐blind, placebo‐controlled dose‐finding study, in this open, long‐term extension study, 154 birch pollen‐allergic patients were enrolled in Germany. Patients were treated with a cumulative dose of 48,000 mTU EP‐088_T502 administered subcutaneously over five pre‐seasonal visits in each of the two treatment years (2021, 2022) with a subsequent follow‐up year in 2023. The primary efficacy endpoint was the combined symptom and medication score (CSMS) during the peak birch pollen season, which was compared with the CSMS of the placebo group during the peak pollen season of 2020. Safety, tolerability, and immunogenicity were also analysed. Results: Compared to the placebo group of the preceding study, median CSMS during the peak birch pollen seasons showed reductions of 47.5% in 2021 ( p < 0.001), 51.8% in 2022 ( p < 0.001), and 36.5% in 2023 ( p < 0.001). Median daily symptom scores were reduced by 40.7% in 2021 ( p < 0.001), 40.7% in 2022 ( p < 0.001), and 25.6% in 2023 ( p < 0.010). Median daily medication scores reached 0.07 in 2021 and 0.04 in 2022 ( p < 0.001) and were reduced by 65.9% in 2023 ( p < 0.003). Immunological responses showed a 4.82‐fold increase in Bet v1 sIgG4 ( p = 0.001) and a marked decrease (−65.5%, p = 0.001) in the sIgE/sIgG4 ratio after the first treatment phase. EP‐088_T502 demonstrated good safety and tolerability, with only six mild to moderate systemic allergic reactions (Grade I/II). No epinephrine was used. Conclusion: In this open‐label study, two consecutive years of pre‐seasonal short‐course allergen immunotherapy (AIT) with EP‐088_T502 markedly reduced symptoms and medication need in patients with birch pollen‐induced rhinoconjunctivitis. Persistent therapeutic effects observed during the follow‐up year, although limited by attrition of the study population, suggest sustained clinical improvement and indicate the potential disease‐modifying impact of this treatment regimen.

20 October 2020 in Allergo Journal International
Verified
Journal Article
Open access
PDF file
PZPetra Zieglmayer
Petra Zieglmayer
Ralph MösgesRalph Mösges
Ralph Mösges
SASilke Allekotte
Silke Allekotte
SWSandra Weissenbaeck
Sandra Weissenbaeck
MMMichael Moser
Michael Moser
SGSonja Güthoff
Sonja Güthoff

15 June 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
EREsther Raskopf
Esther Raskopf
SPSofia Passamera
Sofia Passamera
LKLudger Klimek
Ludger Klimek
OPOliver Pfaar
Oliver Pfaar
CNChristian Neuhof
Christian Neuhof
SPSandra del Pozo
Sandra del Pozo
Background: The mannan-conjugated birch pollen polymerised allergoid EP-088_T502 has previously been shown to reduce allergic symptoms and anti-allergic medication use during the birch pollen season. This confirmatory phase III trial aimed to evaluate the efficacy, safety, tolerability, and immunologic effects of six pre-seasonal subcutaneous injections.Methods: In this DBPC trial, 278 participants with birch pollen–induced allergic rhinoconjunctivitis (ARC) received either placebo or a cumulative dose of 28,000 mTU EP-088_T502. The primary efficacy endpoint was the combined symptom and medication score (CSMS) during the peak birch pollen season. Safety, tolerability, health-related quality of life (QoL), and immunologic parameters were also assessed.Results: EP-088_T502 significantly reduced the CSMS during the peak birch pollen season compared with placebo (mean absolute difference [MAD] −0.31; p=0.016, FAS). In the PP and Complete Cases sets, MAD were -0.36 (p=0.012) and -0.51 (p=0.013), respectively. Health-related QoL improved by 20% in the EP-088_T502 group compared with placebo during the peak season (p<0.005). EP-088_T502 increased Bet v1-specific IgG4 levels after treatment compared with placebo (6.4-fold; p<0.0001). The Bet v1-specific IgE/IgG4 ratio was reduced by 73% from baseline and by 69% compared with placebo (both p<0.0001). Thirteen systemic allergic reactions occurred, including one grade III systemic reaction considered related to EP-088_T502.Conclusions: EP-088_T502 significantly improved symptom and medication scores in participants with birch pollen–induced ARC and induced a substantial Bet v1-specific IgG4 response. The higher cumulative dose was associated with enhanced immunologic effects and an acceptable safety and tolerability profile.

4 October 2026 in Clinical and Translational Allergy
Verified
Journal Article
Open access
PDF file
EREsther Raskopf
Esther Raskopf
SPSofia Passamera
Sofia Passamera
LKLudger Klimek
Ludger Klimek
OPOliver Pfaar
Oliver Pfaar
CNChristian Neuhof
Christian Neuhof
SPSandra del Pozo
Sandra del Pozo
Background: The mannan‐conjugated birch pollen polymerised allergoid EP‐088_T502 has previously been shown to reduce allergic symptoms and anti‐allergic medication use during the birch pollen season. This confirmatory phase III trial aimed to evaluate the efficacy, safety, tolerability, and immunologic effects of EP‐088_T502 administered as eight subcutaneous injections over six pre‐seasonal treatment visits. Methods: In this double‐blind, placebo‐controlled (DBPC) trial, 278 participants with birch pollen–induced allergic rhinoconjunctivitis (ARC) received either placebo or a cumulative dose of 28,000 mannan therapeutic units (mTU) of EP‐088_T502. The primary efficacy endpoint was the combined symptom and medication score (CSMS) during the peak birch pollen season. Safety, tolerability, health‐related quality of life (QoL), and immunologic parameters were also assessed. Results: In the full analysis set (FAS), EP‐088_T502 significantly reduced the CSMS during the peak birch pollen season compared with placebo (mean absolute difference [MAD] −0.31; 95% confidence interval [CI], −0.56 to −0.05; p = 0.0169). In the per‐protocol (PP) and complete‐case sets, the corresponding MADs were −0.36 ( p = 0.012) and −0.51 ( p = 0.013), respectively. Health‐related QoL improved by 20% in the EP‐088_T502 group compared with placebo during the peak season ( p < 0.005). EP‐088_T502 increased Bet v 1‐specific immunoglobulin G4 (IgG4) levels after treatment compared with placebo (6.4‐fold; p < 0.0001). The Bet v 1‐specific immunoglobulin E (IgE)/IgG4 ratio was reduced by 73% from baseline and by 69% compared with placebo (both p < 0.0001). Thirteen systemic allergic reactions occurred, including one grade III systemic reaction considered related to EP‐088_T502. Conclusions: EP‐088_T502 significantly improved symptom and medication scores in participants with birch pollen–induced ARC and induced a substantial Bet v 1‐specific IgG4 response. The 28,000 mTU regimen induced a substantial immunological response and showed an acceptable safety and tolerability profile.